Understanding how RET-driven cancers respond to treatment and develop resistance
Predicting sensitivity and resistance in RET-driven cancers
This study is looking at how well a new cancer treatment called selpercatinib works for people with certain types of lung and thyroid cancers, and it aims to find out why some patients do better than others by examining their tumor samples.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11039932 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of selpercatinib, a selective RET inhibitor, in treating RET-dependent cancers, such as certain lung and thyroid cancers. It aims to identify why some patients respond well to the treatment while others do not, by analyzing genetic and non-genetic factors in tumor samples. The study will utilize advanced sequencing techniques on biopsies from patients before and after treatment to uncover mechanisms of resistance. By understanding these factors, the research seeks to improve treatment strategies for patients with RET-driven cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with RET-dependent cancers, particularly those who have undergone treatment with selpercatinib.
Not a fit: Patients with cancers that are not driven by RET mutations or fusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with RET-driven cancers by overcoming resistance to current therapies.
How similar studies have performed: Previous research has shown promising results with selective RET inhibitors in treating RET-driven cancers, indicating a potential for success in this approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Drilon, Alexander — Sloan-Kettering Inst Can Research
- Study coordinator: Drilon, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.